Piper Sandler maintains Neurocrine Biosciences at Overweight, raises price target to $215 from $210

Bernstein reiterated an Outperform rating and $218 price target on Neurocrine Biosciences (NBIX) after its Q3 2026 earnings beat estimates. Revenue was $1.12B, up 41% YoY, with Crenessity sales at $211M. Analysts highlight strong drug performance and growth momentum. Other firms also raised price targets.

Guggenheim raised its price target on Neurocrine Biosciences (NBIX) to $224 from $207, citing strong revenue growth and raised guidance. The company reported $1.12B in revenue, up 41% YoY, with Ingrezza sales exceeding estimates. Neurocrine also raised its 2026 revenue forecast to $2.9B-$2.925B. Analysts like Cantor Fitzgerald and Baird maintain bullish ratings.

Neurocrine Biosciences Inc. (NBIX) stock rose 14.3% after strong Q3 earnings, with revenue of $1.12B (up from $794.9M YoY) and adjusted EPS of $3.29 (up from $2.17). The company also reported positive clinical data and expanded its pipeline, including a new Phase 2 trial for Alzheimer's treatment. Management raised FY26 revenue guidance to $2.9B–$2.925B, below consensus of $3.9B.

Neurocrine Biosciences (NBIX) stock rose 15.1% after reporting Q3 adjusted earnings of $3.29 per share, beating estimates by 72%, and revenue of $1.12 billion, up 41% YoY. The company surpassed $1 billion in net product sales for the first time, driven by its top products. Analysts raised price targets, with Baird setting a $225 target. Management increased 2026 INGREZZA sales guidance to $2.9-$2.925 billion.

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

Neurocrine Biosciences (NBIX) shares rose 15% after Q3 2026 results showed $1.1B revenue, up 41% YoY, beating estimates. The company also raised guidance.